ARTICLE | Finance
venBio Selects
venBio Select Fund targets public biotech M&A and partnership candidates
October 11, 2010 7:00 AM UTC
The venBio Select Fund was launched on July 1 and already boasts a nice three-month return due to the proposed takeout of ZymoGenetics Inc. (NASDAQ:ZGEN) by Bristol-Myers Squibb Co. (NYSE:BMY), the fund's Kurt von Emster told Ebb & Flow.
The pharma's tender offer for $885 million in cash ($9.75 per share) is an 84% premium to the biotech's close prior to the deal's announcement...